A Study of AdAPT-001 in Subjects With Sarcoma and Refractory Solid Tumors
A phase 2 trial of AdAPT-001 in sarcomas, run by EpicentRx, Inc., active and no longer recruiting.
Overview
A Study of AdAPT-001 in Subjects With Sarcoma and Refractory Solid Tumors is a phase 2 interventional study registered as NCT04673942 by EpicentRx, Inc., with 140 participants enrolled, started 2021-03-29 and due to reach its primary completion in 2026-12-01. Interventions recorded: AdAPT-001 and Checkpoint Inhibitor, Immune.
Similar pages
not linked directly; found by shared links- TrialRRx-001 for Reducing Oral Mucositis in Patients Receiving Chemotherapy and Radiation for Head and Neck Cancer
Shares EpicentRx and the tag pipeline.
- TrialA Phase 3, Controlled, Open-label, Global Randomized Study of RRx-001 With a Platinum Doublet or a Platinum Doublet in Small Cell Lung Cancer
Shares EpicentRx and the tag pipeline.
- TrialClinical Study of VG161 in the Treatment of Advanced Bone and Soft Tissue Sarcoma
Shares Sarcomas (soft tissue, bone, GIST) and the tag pipeline.
- TrialA Study of RNK08954 in Subjects With Advanced Solid Tumors With KRAS ((Kirsten Rat Sarcoma) G12D Mutation
Shares Sarcomas (soft tissue, bone, GIST) and the tag pipeline.
- TrialFirst-in-Human Study of ADCE-D01 in Soft Tissue Sarcoma
Shares Sarcomas (soft tissue, bone, GIST) and the tag pipeline.
- TrialA Study Evaluating the Efficacy and Safety of Risvutatug Rezetecan in Participants With Advanced Sarcomas (EMBOLD Sarcoma-202)
Shares Sarcomas (soft tissue, bone, GIST) and the tag pipeline.
- TrialIntratumoral Injection of IP-001 Following Thermal Ablation in Patients With CRC, NSCLC, and STS
Shares Sarcomas (soft tissue, bone, GIST) and the tag pipeline.
- TrialIvosidenib in Participants With Locally Advanced or Metastatic Conventional Chondrosarcoma Untreated or Previously Treated With 1 Systemic Treatment Regimen
Shares Sarcomas (soft tissue, bone, GIST) and the tag pipeline.